3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Pancreatic Neoplasms
1
Gastrointestinal Neoplasms
1
Colorectal Neoplasms
1
Interventions
Oxaliplatin
300
Fluorouracil
273
Bevacizumab
238
Gemcitabine
235
Leucovorin
213
Capecitabine
207
pembrolizumab
202
Nivolumab
158
Irinotecan
158
Cisplatin
150
Specimen Handling
144
Magnetic Resonance Spectroscopy
130
130-nm albumin-bound paclitaxel
118
Paclitaxel
109
durvalumab
106
Cetuximab
104
Radiotherapy
99
atezolizumab
94
Drug Therapy
94
Biopsy
93
tislelizumab
81
Albumin-Bound Paclitaxel
81
Taxes
74
Folfox protocol
68
lenvatinib
67
Carboplatin
66
regorafenib
60
Blood Specimen Collection
60
sintilimab
54
Ipilimumab
53
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
romiplostim
×
Gastrointestinal
×
1 year
×
Clear all
NCT03362177
2026-02-11
RECITE
Amgen
Phase 3
Completed
165 enrolled
22 charts